A novel clinically relevant approach to tip the balance toward regulation in stringent transplant model

Transplantation

Volumn 90, Issue 3, 2010, Pages 260-269

  D'Addio, Francesca ^a,b   Yuan, Xueli ^a   Habicht, Antje ^a,c   Williams, John ^d   Ruzek, Melanie ^d   Iacomini, John ^a   Turka, Laurence A ^e   Sayegh, Mohamed H ^a   Najafian, Nader ^a   Ansari, M Javeed ^a,f  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d GENZYME CORPORATION   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Costimulation; Homeostatic proliferation; Regulation; Sirolimus; T cell depletion; Transplantation

Indexed keywords

ABATACEPT; ALLOANTIGEN; ANTIBODY; PC 61; RAPAMYCIN; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CD25+ T LYMPHOCYTE; CELL PROLIFERATION; DRUG INHIBITION; EFFECTOR CELL; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; GRAFT SURVIVAL; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOREGULATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; ORGAN TRANSPLANTATION; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SKIN ALLOGRAFT; SKIN TRANSPLANTATION; T CELL DEPLETION; TRANSPLANTATION TOLERANCE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTILYMPHOCYTE SERUM; CELL DIFFERENTIATION; CELL PROLIFERATION; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY; HOMEOSTASIS; IMMUNOCONJUGATES; IMMUNOLOGIC MEMORY; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, INBRED DBA; MICE, INBRED ICR; RABBITS; SIROLIMUS; SKIN TRANSPLANTATION; T-LYMPHOCYTES, REGULATORY; TIME FACTORS; TRANSPLANTATION TOLERANCE; TRANSPLANTATION, HOMOLOGOUS;

EID: 77955395369     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181e64217     Document Type: Article

References (49)

1. Zheng XX, Sanchez-Fueyo A, Domenig C, et al. The balance of deletion and regulation in allograft tolerance. Immunol Rev 2003; 196: 75.
2. Shevach EM, DiPaolo RA, Andersson J, et al. The lifestyle of naturally occurring CD4+ CD25+ Foxp3+ regulatory T cells. Immunol Rev 2006; 212: 60.
3. Sakaguchi S, Ono M, Setoguchi R, et al. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 2006; 212: 8.
4. Rouse BT, Sarangi PP, Suvas S. Regulatory T cells in virus infections. Immunol Rev 2006; 212: 272.
5. Aluvihare VR, Kallikourdis M, Betz AG. Regulatory T cells mediate maternal tolerance to the fetus. Nat Immunol 2004; 5: 266.
6. Joffre O, Santolaria T, Calise D, et al. Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytes. Nat Med 2008; 14: 88.
7. Xia G, He J, Zhang Z, et al. Targeting acute allograft rejection by immunotherapy with ex vivo-expanded natural CD4+ CD25+ regulatory T cells. Transplantation 2006; 82: 1749.
8. Bingaman AW, Farber DL. Memory T cells in transplantation: Generation, function, and potential role in rejection. Am J Transplant 2004; 4: 846.
9. Rothstein DM. Immunosuppression and regulation: Cast in new light? J Am Soc Nephrol 2006; 17: 2644.
10. Starzl TE, Marchioro TL, Hutchinson DE, et al. The clinical use of antilymphocyte globulin in renal homotransplantation. Transplantation 1967; 5 (Suppl): 1100.
11. Beiras-Fernandez A, Thein E, Hammer C. Induction of immunosuppression with polyclonal antithymocyte globulins: An overview. Exp Clin Transplant 2003; 1: 79.
12. Genestier L, Fournel S, Flacher M, et al. Induction of Fas (Apo-1, CD95)-mediated apoptosis of activated lymphocytes by polyclonal antithymocyte globulins. Blood 1998; 91: 2360.
13. Michallet MC, Preville X, Flacher M, et al. Functional antibodies to leukocyte adhesion molecules in antithymocyte globulins. Transplantation 2003; 75: 657.
14. Lowsky R, Takahashi T, Liu YP, et al. Protective conditioning for acute graft-versus-host disease. N Engl J Med 2005; 353: 1321.
15. Kang SM, Tang Q, Bluestone JA. CD4+CD25+ regulatory T cells in transplantation: Progress, challenges and prospects. Am J Transplant 2007; 7: 1457.
16. Brennan DC. Faith supported by reason: Mechanistic support for the use of polyclonal antibodies in transplantation. Transplantation 2003; 75: 577.
17. Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia 2007; 21: 1387.
18. Rebellato LM, Gross U, Verbanac KM, et al. A comprehensive definition of the major antibody specificities in polyclonal rabbit antithymocyte globulin. Transplantation 1994; 57: 685.
19. Lopez M, Clarkson MR, Albin M, et al. A novel mechanism of action for anti-thymocyte globulin: Induction of CD4+CD25+Foxp3+ regulatory T cells. J Am Soc Nephrol 2006; 17: 2844.
20. Huang Y, Parker M, Xia C, et al. Rabbit polyclonal mouse antithymocyte globulin administration alters dendritic cell profile and function in NOD mice to suppress diabetogenic responses. J Immunol 2009; 182: 4608.
21. Neujahr DC, Chen C, Huang X, et al. Accelerated memory cell homeostasis during T cell depletion and approaches to overcome it. JIm-munol2006; 176: 4632.
22. Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 2005; 105:4743.
23. Basu S, Golovina T, Mikheeva T, et al. Cutting edge: Foxp3-mediated induction of pim 2 allows human T regulatory cells to preferentially expand in rapamycin. J Immunol 2008; 180: 5794.
24. Taylor PA, Noelle RJ, Blazar BR. CD4(+)CD25(+) immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade. J Exp Med 2001; 193: 1311.
25. vanMaurikA, HerberM, WoodKJ, et al. Cutting edge: CD4+CD25 + alloantigen-specific immunoregulatory cells that can prevent CD8+ T cell-mediated graft rejection: Implications for anti-CD154 immunotherapy. J Immunol 2002; 169:5401.
26. Coenen JJ, Koenen HJ, van Rijssen E, et al. Tolerizing effects of co-stimulation blockade rest on functional dominance of CD4+CD25 + regulatory T cells. Transplantation 2005; 79: 147.
27. Coenen JJ, Koenen HJ, van Rijssen E, et al. CTLA-4 engagement and regulatory CD4+CD25 + T cells independently control CD8+-mediated responses under costimulation blockade. JImmunol 2006; 176:5240.
28. Larsen CP, Knechtle SJ, Adams A, et al. A new look at blockade of T-cell costimulation: A therapeutic strategy for long-term maintenance immunosuppression. Am J Transplant 2006; 6(5 Pt 1): 876.
29. Simon G, Parker M, Ramiya V, et al. Murine antithymocyte globulin therapy alters disease progression in NOD mice by a time-dependent induction of immunoregulation. Diabetes 2008; 57: 405.
30. Ruzek MC, Waire JS, Hopkins D, et al. Characterization of in vitro antimurine thymocyte globulin-induced regulatory T cells that inhibit graft-versus-host disease in vivo. Blood 2008; 111: 1726.
31. Bonnefoy-Berard N, Vincent C, Revillard JP. Antibodies against functional leukocyte surface molecules in polyclonal antilymphocyte and antithymocyte globulins. Transplantation 1991; 51: 669.
32. Bourdage JS, Hamlin DM. Comparative polyclonal antithymocyte globulin and antilymphocyte/antilymphoblast globulin anti-CD antigen analysis by flow cytometry. Transplantation 1995; 59: 1194.
33. Sayegh MH, Wu Z, Hancock WW, et al. Allograft rejection in a new allospecific CD4+ TCR transgenic mouse. Am J Transplant 2003; 3: 381.
34. Minamimura K, Gao W, Maki T. CD4+ regulatory T cells are spared from deletion by antilymphocyte serum, a polyclonal anti-T cell antibody. J Immunol 2006; 176:4125.
35. Wu Z, Bensinger SJ, Zhang J, et al. Homeostatic proliferation is a barrier to transplantation tolerance. Nat Med 2004; 10: 87.
36. Kasprowicz DJ, Droin N, Soper DM, et al. Dynamic regulation of FoxP3 expression controls the balance between CD4+ T cell activation and cell death. Eur J Immunol 2005; 35: 3424.
37. Xu L, Kitani A, Fuss I, et al. Cutting edge: Regulatory T cells induce CD4 + CD25-Foxp3-T cells or are self-induced to become Th17 cells in the absence of exogenous TGF-beta. J Immunol 2007; 178: 6725.
38. Yang XO, Nurieva R, Martinez GJ, et al. Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity 2008; 29: 44.
39. Komatsu N, Mariotti-Ferrandiz ME, Wang Y, et al. Heterogeneity of natural Foxp3+ T cells: A committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity. Proc Natl Acad Sci\USA 2009; 106: 1903.
40. Gao W, Lu Y, El Essawy B, et al. Contrasting effects of cyclosporine and rapamycin in De novo generation of alloantigen-specific regulatory T cells. Am J Transplant 2007; 7: 1722.
41. Gavin MA, Clarke SR, Negrou E, et al. Homeostasis and anergy of CD4(+)CD25(+) suppressor T cells in vivo. Nat Immunol 2002; 3:33.
42. Curotto De Lafaille MA, Shen S, Olivares-Villagomez D, et al. Do regulatory T cells play a role in the control of homeostatic proliferation? Int Rev Immunol 2005; 24: 269.
43. Xia G, He J, Leventhal JR. Ex vivo-expanded natural CD4+CD25 + regulatory T cells synergize with host T-cell depletion to promote long-term survival of allografts. Am J Transplant 2008; 8: 298.
44. Ndejembi MP, Teijaro JR, Patke DS, et al. Control of memory CD4 T cell recall by the CD28/B7 costimulatory pathway. J Immunol 2006; 177: 7698.
45. Ford ML, Koehn BH, Wagener ME, et al. Antigen-specific precursor frequency impacts T cell proliferation, differentiation, and requirement for costimulation. J Exp Med 2007; 204: 299.
46. Li Y, LiXC, Zheng XX, etal. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med 1999; 5: 1298.
47. Bestard O, Cruzado JM, Mestre M, et al. Achieving donor-specific hyporesponsiveness is associated with FOXP3 + regulatory T cell recruitment in human renal allograft infiltrates. J Immunol 2007; 179: 4901.
48. Hagen KA, Moses CT, Drasler EF, et al. A role for CD28 in lymphopenia-induced proliferation of CD4 T cells. J Immunol 2004; 173: 3909.
49. Minamimura K, Sato K, Yagita H, et al. Strategies to induce marked prolongation of secondary skin allograft survival in alloantigen-primed mice. Am J Transplant 2008; 8: 761.